# CMOEP in the Treatment of Untreated Peripheral T-cell Lymphoma

> **NCT06433362** · PHASE2 · RECRUITING · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 115 (estimated)

## Conditions studied

- Peripheral T Cell Lymphoma

## Interventions

- **DRUG:** CMOEP

## Key facts

- **NCT ID:** NCT06433362
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-01
- **Primary completion:** 2025-06-30
- **Final completion:** 2026-06-30
- **Target enrollment:** 115 (ESTIMATED)
- **Last updated:** 2024-05-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06433362

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06433362, "CMOEP in the Treatment of Untreated Peripheral T-cell Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06433362. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*